63498-15-7Relevant articles and documents
Synthesis of deuterium-labelled trantinterol
Wen, Hongliang,Pan, Li,Zhang, Yingdan,Ma, Jiacheng,Qin, Liqiong,Cheng, Maosheng
, p. 779 - 781 (2013/01/09)
Trantinterol, a selective β2-adrenoceptor agonist, is currently in Phase II clinical trials for the treatment of asthma and bronchitis. The synthesis of deuterium-labelled trantinterol is described. The labelled trantinterol is used as an inter
Synthesis of further amino-halogen-substituted phenyl-aminoethanols
Kruger,Keck,Noll,Pieper
, p. 1612 - 1624 (2007/10/02)
Starting from clenbuterol as a lead structure, new 4-amino-phenyl-aminoethanol analogues have been synthesized by different approaches. In these compounds one or both of the chlorine atoms of clenbuterol are replaced by other residues. This has led to compounds with high intrinsic β2-mimetic and/or β1-blocking activities. 1-(4-Amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butylamino-ethanol hydrochloride (mabuterol) has been selected for clinical development. A detailed description is also given of the syntheses of new intermediate acetophenone derivatives as well as of the resolution of mabuterol into its enantiomers.